HRP20151347T1 - Nova kombinacija - Google Patents
Nova kombinacija Download PDFInfo
- Publication number
- HRP20151347T1 HRP20151347T1 HRP20151347TT HRP20151347T HRP20151347T1 HR P20151347 T1 HRP20151347 T1 HR P20151347T1 HR P20151347T T HRP20151347T T HR P20151347TT HR P20151347 T HRP20151347 T HR P20151347T HR P20151347 T1 HRP20151347 T1 HR P20151347T1
- Authority
- HR
- Croatia
- Prior art keywords
- benazepril
- fixed
- layer
- pimobendan
- combination according
- Prior art date
Links
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 12
- 229960004530 benazepril Drugs 0.000 claims 12
- 229940000425 combination drug Drugs 0.000 claims 12
- 239000010410 layer Substances 0.000 claims 11
- 229960002164 pimobendan Drugs 0.000 claims 10
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 claims 10
- 239000008188 pellet Substances 0.000 claims 6
- 229960003619 benazepril hydrochloride Drugs 0.000 claims 4
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000011241 protective layer Substances 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Edible Oils And Fats (AREA)
Claims (13)
1. Kombinacija s fiksnom dozom, naznačena time što sadrži benazepril-hidroklorid i pimobendan u omjeru od 2:1, u obliku dvoslojne tablete,
gdje sloj s benazeprilom sadrži 2,5, 5 ili 10 mg benazepril-hidroklorida, sadržanog u obliku peleta, te
gdje sloj s pimobendanom sadrži 1,25, 2,5 ili 5 mg pimobendana.
2. Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 1, naznačena time što pelete u sloju s benazeprilom sadrže 5% benazeprila, težinski, po sloju.
3. Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 1 ili 2, naznačena time što pelete s benazeprilom u sloju s benazeprilom su obložene zaštitnim slojem, koji se sastoji od butil-metakrilat–2-dimetilaminoetil-metakrilat–metil-metakrilatnog kopolimera (1:2:1).
4. Kombinacija s fiksnom dozom u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što pelete s benazeprilom u sloju s benazeprilom imaju veličinu čestica od 0,15 do 0,4 mm u promjeru.
5. Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 4, naznačena time što pomoćne tvari u sloju s benazeprilom imaju veličinu čestica od 200 do 400 µm.
6. Kombinacija s fiksnom dozom u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što je sloj s pimobendanom u obliku granulata.
7. Kombinacija s fiksnom dozom u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što sloj s pimobendanom sadrži jantarnu kiselinu.
8. Kombinacija s fiksnom dozom u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što sadrži 1,25 mg pimobendana i 2,5 mg benazeprila, te ima širinu od 6,5 do 7 mm, duljinu od 11,5 do 12 mm i debljinu od 4,0 do 4,5 mm.
9. Kombinacija s fiksnom dozom u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što sadrži 5 mg pimobendana i 10 mg benazeprila, te ima širinu od 10 do 10,5 mm, duljinu od 19 to 19,5 mm i debljinu od 6,5 do 7,5 mm.
10. Kombinacija s fiksnom dozom u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što je namijenjena upotrebi u liječenju kongestivne srčane insuficijencije kod pasa.
11. Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 10, naznačena time što se primjenjuje dva puta dnevno.
12. Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 10 ili 11, naznačena time što su karakteristike otpuštanja za benazepril-hidroklorid i pimobendan ekvivalentne karakteristikama otpuštanja za benazepril-hidroklorid i pimobendan kada se daju kao pojedinačni proizvodi.
13. Postupak proizvodnje kombinacije s fiksnom dozom u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što
a) se dobije pimobendan granulat,
b) se dobiju pelete s benazeprilom,
c) pelete s benazeprilom dobivene u b) dodatno se pomiješaju s pomoćnim tvarima kako bi se dobila smjesa, te
d) granulat i smjesa dobivene u a) i c) se komprimiraju zajedno kako bi se dobila dvoslojna tableta.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195015 | 2011-12-21 | ||
| EP12185714 | 2012-09-24 | ||
| EP12813324.6A EP2793866B2 (en) | 2011-12-21 | 2012-12-19 | Bilayer tablet comprising benazepril hydrochloride and pimobendan |
| PCT/EP2012/076100 WO2013092673A2 (en) | 2011-12-21 | 2012-12-19 | New combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151347T1 true HRP20151347T1 (hr) | 2016-01-01 |
Family
ID=47552987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151347TT HRP20151347T1 (hr) | 2011-12-21 | 2015-12-08 | Nova kombinacija |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10874618B2 (hr) |
| EP (3) | EP3034071B1 (hr) |
| JP (1) | JP6148252B2 (hr) |
| CN (1) | CN104010632B (hr) |
| AU (1) | AU2012357795B2 (hr) |
| BR (1) | BR112014014896A2 (hr) |
| CA (1) | CA2858941C (hr) |
| CL (1) | CL2014001534A1 (hr) |
| CO (1) | CO6970601A2 (hr) |
| CY (1) | CY1117086T1 (hr) |
| DK (2) | DK3034071T3 (hr) |
| ES (2) | ES2560052T5 (hr) |
| HR (1) | HRP20151347T1 (hr) |
| HU (2) | HUE028579T2 (hr) |
| MX (1) | MX365621B (hr) |
| NO (1) | NO3034071T3 (hr) |
| PL (2) | PL3034071T3 (hr) |
| PT (1) | PT3034071T (hr) |
| RS (1) | RS54475B1 (hr) |
| RU (1) | RU2014129508A (hr) |
| SI (1) | SI2793866T1 (hr) |
| WO (1) | WO2013092673A2 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| HUE028579T2 (en) | 2011-12-21 | 2016-12-28 | Novartis Tiergesundheit Ag | New combination |
| ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
| CN113181110A (zh) | 2013-07-19 | 2021-07-30 | 勃林格殷格翰动物保健有限公司 | 含有防腐的醚化的环糊精衍生物的液体水性药物组合物 |
| EP3106150B1 (en) | 2013-12-04 | 2021-07-28 | Boehringer Ingelheim Vetmedica GmbH | Improved pharmaceutical compositions of pimobendan |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| CN112618505B (zh) * | 2020-12-30 | 2022-11-15 | 南京朗博特动物药业有限公司 | 一种宠物用含有贝那普利和匹莫苯丹的复方药物组合物及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364646A (en) | 1990-01-10 | 1994-11-15 | Dr. Karl Thomae Gmbh | Oral pharmaceutical forms of pimobendan |
| US6162802A (en) | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| EP1365761A1 (en) | 2000-12-18 | 2003-12-03 | Novartis AG | Therapeutic combination of amlodipine and benazepril |
| WO2003075842A2 (en) | 2002-03-08 | 2003-09-18 | Teva Pharmeceuticals Usa, Inc. | Stable formulations of angiotensin converting enzyme (ace) inhibitors |
| CO5400144A1 (es) | 2002-03-11 | 2004-05-31 | Novartis Ag | Compuestos organicos |
| MXPA06004369A (es) | 2003-10-20 | 2006-06-14 | Novartis Ag | Uso de compuestos organicos. |
| GB2394660A (en) | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) * | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| JP2005281283A (ja) | 2004-03-31 | 2005-10-13 | Akira Matsumori | ベンズイミダゾール系薬剤の併用医薬 |
| WO2006085208A2 (en) | 2005-02-11 | 2006-08-17 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine and benazepril |
| JP2010500374A (ja) * | 2006-08-08 | 2010-01-07 | エーシーシーユー−ブレイク テクノロジーズ，インク． | 複数の活性セグメントを含む薬剤の錠剤 |
| WO2008095263A1 (en) | 2007-02-09 | 2008-08-14 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
| FR2917975B1 (fr) * | 2007-06-26 | 2009-10-16 | Ceva Sante Animale Sa | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains |
| WO2010055119A2 (en) | 2008-11-17 | 2010-05-20 | Novartis Ag | Pharmaceutical composition comprising pimobendan |
| WO2010097501A2 (en) | 2009-02-26 | 2010-09-02 | Orion Corporation | A combination treatment |
| WO2011111066A2 (en) | 2010-03-12 | 2011-09-15 | Connexios Life Sciences Pvt. Ltd. | Composition and uses thereof |
| HUE028579T2 (en) | 2011-12-21 | 2016-12-28 | Novartis Tiergesundheit Ag | New combination |
-
2012
- 2012-12-19 HU HUE12813324A patent/HUE028579T2/en unknown
- 2012-12-19 US US14/366,900 patent/US10874618B2/en active Active
- 2012-12-19 PT PT151932696T patent/PT3034071T/pt unknown
- 2012-12-19 ES ES12813324T patent/ES2560052T5/es active Active
- 2012-12-19 NO NO15193269A patent/NO3034071T3/no unknown
- 2012-12-19 EP EP15193269.6A patent/EP3034071B1/en active Active
- 2012-12-19 PL PL15193269T patent/PL3034071T3/pl unknown
- 2012-12-19 MX MX2014007700A patent/MX365621B/es active IP Right Grant
- 2012-12-19 DK DK15193269.6T patent/DK3034071T3/en active
- 2012-12-19 BR BR112014014896A patent/BR112014014896A2/pt active Search and Examination
- 2012-12-19 EP EP17199031.0A patent/EP3320894A1/en not_active Withdrawn
- 2012-12-19 ES ES15193269.6T patent/ES2656412T3/es active Active
- 2012-12-19 HU HUE15193269A patent/HUE035830T2/en unknown
- 2012-12-19 PL PL12813324.6T patent/PL2793866T5/pl unknown
- 2012-12-19 JP JP2014547959A patent/JP6148252B2/ja active Active
- 2012-12-19 EP EP12813324.6A patent/EP2793866B2/en active Active
- 2012-12-19 DK DK12813324.6T patent/DK2793866T4/da active
- 2012-12-19 AU AU2012357795A patent/AU2012357795B2/en active Active
- 2012-12-19 CN CN201280062716.3A patent/CN104010632B/zh active Active
- 2012-12-19 CA CA2858941A patent/CA2858941C/en active Active
- 2012-12-19 WO PCT/EP2012/076100 patent/WO2013092673A2/en active Application Filing
- 2012-12-19 RS RS20150850A patent/RS54475B1/en unknown
- 2012-12-19 RU RU2014129508A patent/RU2014129508A/ru unknown
- 2012-12-19 SI SI201230374T patent/SI2793866T1/sl unknown
-
2014
- 2014-06-03 CO CO14118785A patent/CO6970601A2/es active IP Right Grant
- 2014-06-11 CL CL2014001534A patent/CL2014001534A1/es unknown
-
2015
- 2015-12-08 HR HRP20151347TT patent/HRP20151347T1/hr unknown
- 2015-12-30 CY CY20151101200T patent/CY1117086T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151347T1 (hr) | Nova kombinacija | |
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| HRP20211606T1 (hr) | Oralni farmaceutski pripravci dabigatran-eteksilata | |
| WO2011106416A3 (en) | Abuse-resistant formulations | |
| MX336861B (es) | Formulacion de farmaco resistente al abuso. | |
| CL2013003363A1 (es) | Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado recubierto que comprende un opioide y un polimero fisiologicamente aceptable, recubierto con un polimero soluble en agua; donde el multiparticulado forma una fase discontinua dentro de la matriz. | |
| WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| WO2010136739A3 (fr) | Compositions pharmaceutiques flottantes à libération contrôlée | |
| HRP20170734T1 (hr) | Povećana biodostupnost lijeka u terapiji naltreksonom | |
| WO2017070131A3 (en) | Particles for malodor reduction | |
| MX362838B (es) | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. | |
| JP2013540807A5 (hr) | ||
| WO2015003478A3 (zh) | 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 | |
| WO2009034431A3 (en) | Controlled-release dosage forms for varenicline | |
| HRP20140479T1 (hr) | Oralna farmaceutska tableta za kontrolirano otpuštanje mesalazina i postupak njezine proizvodnje | |
| WO2011140446A3 (en) | Pharmaceutical formulations | |
| WO2014027334A3 (es) | Composicion farmacéutica oral en forma de microesferas y proceso de elaboración | |
| WO2015003479A3 (zh) | 一种适用于婴幼儿及儿童的口服固体颗粒及其制备方法 | |
| WO2012052834A3 (en) | Multiple unit particulate system comprising metoprolol succinate | |
| PL402191A1 (pl) | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję | |
| JP2014527506A5 (hr) | ||
| PH12016500693A1 (en) | Slow-release solid oral compositions | |
| EP2497464A3 (en) | Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture | |
| MX2015010449A (es) | Composicion farmaceutica multiparticulada que comprende una multitud de dos clases de granulos. | |
| EP2345408A3 (en) | Acid labile drug formulations |